Role of 18F-FDG PET in detecting primary site in the patient with primary unknown carcinoma.
The aim of this study was to verify the effectiveness of positron emission tomography (PET) in detecting primary sites in carcinoma of unknown primary (CUP) patients. In this study, CUP represented a group of heterogeneous tumors that shared the clinical manifestation of metastatic carcinoma with no obvious primary site at the time of first diagnosis, which included clinical investigations, computed tomography, magnetic resonance imaging and panendoscopy. We reviewed the records of 24 patients with CUP between January 1995 and December 2009. The patients who demonstrated additional tracer uptake sites other than previously known metastatic lesions by PET scan were done direct biopsies for the sites of accumulation. Patients who had a negative PET scan or for whom the primary site could not be identified by direct biopsies underwent examination under anesthesia of the at-risk occult tumor sites. PET scan demonstrated focal accumulation suspicious for primary tumor in 12 (50.0%) of 24 patients: tonsil 5, nasopharynx 3, hypopharynx 1, tongue 1, larynx 1, and maxillary sinus 1. A subsequent biopsy of these sites revealed primary cancer in 9 (37.5%) of 24 patients: tonsil 5, nasopharynx 1, hypopharynx 1, tongue 1, and maxillary sinus 1. In the remaining three patients, no malignant cells were found by the biopsy of the accumulated area: nasopharynx 2, larynx 1. PET scans increase the yield of primary tumor by 37.5%. The sensitivity, specificity for PET scan were 80.8, 76.9%, respectively. PET scanning is useful in detecting primary cancer of CUP patients.
Yabuki
Kenichiro
K
Department of Otorhinolaryngology, and Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, 3-9 Fukuura, Yokohama, Kanazawa 236-0004, Japan. kenichirouy@jadecom.jp
Tsukuda
Mamoru
M
Horiuchi
Choichi
C
Taguchi
Takahide
T
Nishimura
Goshi
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy / Q000379:methods; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000556:secondary*; D003952:Diagnostic Imaging; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D019788:Fluorodeoxyglucose F18; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009382:Neoplasms, Unknown Primary / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D018709:Statistics, Nonparametric; D015996:Survival Rate
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
J Nucl Med. 2008 Mar;49(3):480-508
18287273
Cancer. 2004 Dec 1;101(11):2641-9
15517576
Auris Nasus Larynx. 2009 Apr;36(2):199-204
18632233
Nucl Med Commun. 2007 May;28(5):365-71
17414886
Radiology. 2005 Jan;234(1):227-34
15564390
Int J Oral Maxillofac Surg. 1997 Apr;26(2):112-5
9151165
Eur J Nucl Med Mol Imaging. 2005 May;32(5):589-92
15726356
J Nucl Med. 2000 May;41(5):816-22
10809197
Radiology. 1999 Jan;210(1):177-81
9885604
Eur J Cancer. 1999 Jul;35(7):1076-82
10533451
Head Neck. 2008 Jan;30(1):28-34
17657782
Otolaryngol Head Neck Surg. 2000 Sep;123(3):294-301
10964310
Cancer. 1999 Jul 1;86(1):114-8
10391570
Cancer. 1998 Mar 15;82(6):1160-6
9506364
Head Neck. 2008 Apr;30(4):471-8
18023031
Nucl Med Commun. 2008 Sep;29(9):791-802
18677207
Laryngoscope. 1999 Jun;109(6):880-5
10369275
Cancer J Sci Am. 1999 Jul-Aug;5(4):214-8
10439166
Clin Oncol (R Coll Radiol). 2003 Dec;15(8):461-6
14690001
Acta Otorhinolaryngol Ital. 2005 Feb;25(1):2-12
16080309
Oral Oncol. 1999 Jul;35(4):390-4
10645404
Laryngoscope. 2002 Nov;112(11):2009-14
12439171
Laryngoscope. 2009 Jan;119(1):102-6
19117304